# A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations

> **NCT06800196** · PHASE1 · NOT_YET_RECRUITING · sponsor: **KinoTeck Therapeutics Co., Ltd** · enrollment: 151 (estimated)

## Conditions studied

- Solid Tumors with FGFR2 Alterations, Adult

## Interventions

- **DRUG:** KNT-0916

## Key facts

- **NCT ID:** NCT06800196
- **Lead sponsor:** KinoTeck Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 151 (ESTIMATED)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06800196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06800196, "A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06800196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*